GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Island Pharmaceuticals Ltd (ASX:ILA) » Definitions » ROE %

Island Pharmaceuticals (ASX:ILA) ROE % : -190.67% (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Island Pharmaceuticals ROE %?

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Island Pharmaceuticals's annualized net income for the quarter that ended in Dec. 2023 was A$-2.31 Mil. Island Pharmaceuticals's average Total Stockholders Equity over the quarter that ended in Dec. 2023 was A$1.21 Mil. Therefore, Island Pharmaceuticals's annualized ROE % for the quarter that ended in Dec. 2023 was -190.67%.

The historical rank and industry rank for Island Pharmaceuticals's ROE % or its related term are showing as below:

ASX:ILA' s ROE % Range Over the Past 10 Years
Min: -133.7   Med: -48.65   Max: -33.24
Current: -133.7

During the past 3 years, Island Pharmaceuticals's highest ROE % was -33.24%. The lowest was -133.70%. And the median was -48.65%.

ASX:ILA's ROE % is ranked worse than
82.35% of 1360 companies
in the Biotechnology industry
Industry Median: -43.445 vs ASX:ILA: -133.70

Island Pharmaceuticals ROE % Historical Data

The historical data trend for Island Pharmaceuticals's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Island Pharmaceuticals ROE % Chart

Island Pharmaceuticals Annual Data
Trend Jun21 Jun22 Jun23
ROE %
-33.24 -48.65 -92.74

Island Pharmaceuticals Semi-Annual Data
Jun20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
ROE % Get a 7-Day Free Trial -27.74 -69.63 -89.20 -104.03 -190.67

Competitive Comparison of Island Pharmaceuticals's ROE %

For the Biotechnology subindustry, Island Pharmaceuticals's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Island Pharmaceuticals's ROE % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Island Pharmaceuticals's ROE % distribution charts can be found below:

* The bar in red indicates where Island Pharmaceuticals's ROE % falls into.



Island Pharmaceuticals ROE % Calculation

Island Pharmaceuticals's annualized ROE % for the fiscal year that ended in Jun. 2023 is calculated as

ROE %=Net Income (A: Jun. 2023 )/( (Total Stockholders Equity (A: Jun. 2022 )+Total Stockholders Equity (A: Jun. 2023 ))/ count )
=-2.83/( (4.318+1.785)/ 2 )
=-2.83/3.0515
=-92.74 %

Island Pharmaceuticals's annualized ROE % for the quarter that ended in Dec. 2023 is calculated as

ROE %=Net Income (Q: Dec. 2023 )/( (Total Stockholders Equity (Q: Jun. 2023 )+Total Stockholders Equity (Q: Dec. 2023 ))/ count )
=-2.31/( (1.785+0.638)/ 2 )
=-2.31/1.2115
=-190.67 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is two times the semi-annual (Dec. 2023) net income data. ROE % is displayed in the 30-year financial page.


Island Pharmaceuticals  (ASX:ILA) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=-2.31/1.2115
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-2.31 / 0)*(0 / 1.9075)*(1.9075 / 1.2115)
=Net Margin %*Asset Turnover*Equity Multiplier
=N/A %*0*1.5745
=ROA %*Equity Multiplier
=N/A %*1.5745
=-190.67 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=-2.31/1.2115
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (-2.31 / -2.31) * (-2.31 / -4.264) * (-4.264 / 0) * (0 / 1.9075) * (1.9075 / 1.2115)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 1 * 0.5417 * N/A % * 0 * 1.5745
=-190.67 %

Note: The net income data used here is two times the semi-annual (Dec. 2023) net income data. The Revenue data used here is two times the semi-annual (Dec. 2023) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


Island Pharmaceuticals ROE % Related Terms

Thank you for viewing the detailed overview of Island Pharmaceuticals's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Island Pharmaceuticals (ASX:ILA) Business Description

Traded in Other Exchanges
N/A
Address
697 Burke Road, Suite 201, Camberwell, VIC, AUS, 3124
Island Pharmaceuticals Ltd is a drug research and repurposing company focused on developing preventative or therapeutic drugs for viral infections. Its lead asset ISLA-101 is a drug with a well-established safety profile, being repurposed for the prevention and treatment of dengue fever and another mosquito (or vector) borne diseases.

Island Pharmaceuticals (ASX:ILA) Headlines

No Headlines